It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We have shown that both reactive oxygen species (ROS) and paxillin tyrosine phosphorylation regulate LPS-induced human lung endothelial permeability. Mitochondrial ROS (mtROS) is known to increase endothelial cell (EC) permeability which requires dynamic change in mitochondrial morphology, events that are likely to be regulated by paxillin. Here, we investigated the role of paxillin and its tyrosine phosphorylation in regulating LPS-induced mitochondrial dynamics, mtROS production and human lung microvascular EC (HLMVEC) dysfunction. LPS, in a time-dependent manner, induced higher levels of ROS generation in the mitochondria compared to cytoplasm or nucleus. Down-regulation of paxillin expression with siRNA or ecto-expression of paxillin Y31F or Y118F mutant plasmids attenuated LPS-induced mtROS in HLMVECs. Pre-treatment with MitoTEMPO, a scavenger of mtROS, attenuated LPS-induced mtROS, endothelial permeability and VE-cadherin phosphorylation. Further, LPS-induced mitochondrial fission in HLMVECs was attenuated by both a paxillin siRNA, and paxillin Y31F/Y118F mutant. LPS stimulated phosphorylation of dynamin-related protein (DRP1) at S616, which was also attenuated by paxillin siRNA, and paxillinY31/Y118 mutants. Inhibition of DRP1 phosphorylation by P110 attenuated LPS-induced mtROS and endothelial permeability. LPS challenge of HLMVECs enhanced interaction between paxillin, ERK, and DRP1, and inhibition of ERK1/2 activation with PD98059 blocked mitochondrial fission. Taken together, these results suggest a key role for paxillin tyrosine phosphorylation in LPS-induced mitochondrial fission, mtROS generation and EC barrier dysfunction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Illinois at Chicago, Department of Pharmacology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); Medical School of Ningbo University, The Affiliated Hospital of Medical School, Ningbo, China (GRID:grid.203507.3) (ISNI:0000 0000 8950 5267)
2 University of Illinois at Chicago, Department of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
3 University of Illinois at Chicago, Department of Pharmacology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
4 University of Arizona Health Sciences, Department of Medicine, College of Medicine, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
5 University of Arizona Health Sciences, Departments of Cellular and Molecular Medicine, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X); University of Arizona Health Sciences, Department of Medicine, College of Medicine, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
6 University of Illinois at Chicago, Department of Pharmacology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); University of Illinois at Chicago, Department of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)




